Kidney biopsy

Kidney biopsy is used when clinical evidence suggests glomerulonephritis in a person with HCV infection. Its decisive significance is that it does more than confirm renal involvement: it identifies the underlying lesion, clarifies competing pathological explanations, and can determine whether treatment should address HCV, immune-complex injury, transplantation-related pathology, or another process.

Indications and Diagnostic Role

International guidance recommends that patients with HCV infection undergo at least annual testing for proteinuria, hematuria, and estimated glomerular filtration rate. When these assessments provide clinical evidence of glomerulonephritis, kidney biopsy is recommended. Early recognition of HCV-associated glomerular disease may improve clinical outcomes, particularly because renal injury can range from mild urinary abnormalities to nephritic or nephrotic syndromes and progressive loss of kidney function.

The procedure is especially important in the setting of mixed cryoglobulinemia. HCV is the major cause of this systemic vasculitis, whose manifestations may include arthralgias, Raynaud phenomena, purpura, peripheral neuropathy, hypocomplementemia, and kidney disease. Kidney involvement commonly appears as proteinuria, hematuria, and variable reduction in estimated glomerular filtration rate; acute nephritic syndrome occurs in approximately 25% of affected patients and nephrotic syndrome in approximately 20%. Extra-renal signs can precede renal disease by several years, so biopsy provides a means of defining kidney injury when the clinical history is prolonged or incomplete.

What the Biopsy Can Reveal

The characteristic lesion associated with HCV is cryoglobulinemic glomerulonephritis, usually a type I membranoproliferative glomerulonephritis. Light microscopy may show marked glomerular hypercellularity caused by infiltration of capillary loops with mononuclear and polymorphonuclear leukocytes. It may also demonstrate accentuated lobulation, increased mesangial matrix and cellularity, endothelial swelling, splitting of the capillary basement membrane, intracapillary thrombi, and eosinophilic material representing precipitated immune complexes or cryoglobulins. Small- and medium-sized renal-artery vasculitis can occur as well.

Immunofluorescence typically demonstrates IgM, IgG, and C3 in the mesangium and along capillary walls. Electron microscopy usually identifies subendothelial immune complexes, sometimes with fibrillar or immunotactoid organization suggestive of cryoglobulin deposits. These findings connect the renal lesion to the systemic immune-complex process rather than treating HCV merely as an incidental laboratory finding.

The clinical appearance remains variable even when the biopsy establishes the same broad disease mechanism. Patients may have persistent non-nephrotic proteinuria and microscopic hematuria with preserved renal function, or they may present with nephrotic syndrome, macroscopic hematuria, and acute renal failure. In HCV and HIV coinfection, the combination of systemic manifestations, laboratory abnormalities, and renal findings should raise suspicion of HCV-induced cryoglobulinemic membranoproliferative glomerulonephritis, but biopsy is generally needed for confirmation because HIV itself can produce several immune-complex glomerular disorders with protean morphology.

Differential Diagnosis and Interpretation

Kidney biopsy prevents the clinical label of HCV-associated disease from becoming a substitute for pathological diagnosis. Typical membranoproliferative glomerulonephritis may occur without circulating cryoglobulins or the usual clinical and laboratory features of cryoglobulinemia. Fibrillary and immunotactoid glomerulopathies have been linked to HCV in some patients, although a direct pathogenic relationship has not been demonstrated. By contrast, proposed connections between HCV and membranous nephropathy or other glomerulonephritides remain weak or absent, and HCV may sometimes be coincidental.

The procedure is also central in transplant recipients. HCV-infected renal allografts can develop immune-complex-mediated glomerulonephritis, including de novo membranoproliferative glomerulonephritis associated with type II mixed cryoglobulinemia. Clinical manifestations may include hypertension, microscopic hematuria, proteinuria, renal dysfunction, and occasionally nephrotic syndrome. Biopsy can show mesangial proliferation, double contours, and parietal IgM and C3 deposits. Cryocrit levels in these allograft cases are often very low, usually below 5%, which may make circulating cryoglobulins difficult to detect; HCV RNA may nevertheless be much more concentrated in the cryocrit than in serum, supporting a pathogenic role for the virus.

In a renal allograft, electron microscopy may be necessary to distinguish membranoproliferative glomerulonephritis from transplant glomerulopathy. Membranoproliferative glomerulonephritis is associated with subendothelial electron-dense deposits, whereas transplant glomerulopathy shows radiolucent areas in the glomerular basement membrane. The two lesions can coexist, allowing biopsy to expose the combined contribution of humoral immunity and autoimmunity to graft injury. It can also identify membranous glomerulonephritis, which has been described in HCV-infected allografts and is usually accompanied by nephrotic syndrome, although a clear HCV-specific mechanism is generally absent.

Relation to Screening and Treatment

Biopsy belongs to a broader diagnostic sequence rather than replacing virological testing. HCV infection is established through both anti-HCV antibodies and detectable HCV RNA; antibody positivity alone cannot distinguish resolved from active infection. Once active chronic infection is identified, assessment must address both hepatic and extrahepatic effects. Liver biopsy or noninvasive fibrosis tests evaluate hepatic injury, while kidney biopsy evaluates suspected glomerular disease.

The pathological result can change the therapeutic balance. The link between HCV and cryoglobulinemic membranoproliferative glomerulonephritis has led clinicians to use antiviral therapy to clear HCV RNA from serum and, in turn, reduce renal injury. In chronic kidney disease, treatment decisions must weigh the severity of kidney and liver disease, treatment risks, cardiovascular comorbidity, and the altered handling of antiviral drugs by diseased kidneys. Pegylated interferon clearance is affected by chronic kidney disease, although hemodialysis does not alter its clearance; ribavirin is renally eliminated and is contraindicated when creatinine clearance is below 50 ml/min because accumulation can cause dramatic anemia.

Kidney biopsy therefore functions as both a diagnostic boundary and a treatment checkpoint. It distinguishes active HCV-related immune-complex injury from unrelated or transplant-specific pathology, gives morphological substance to otherwise nonspecific urinary findings, and helps determine whether viral clearance is a plausible route to renal recovery. In this framework, biopsy is not an isolated procedure but the point at which virology, nephrology, pathology, and transplantation are made clinically answerable to one another.